Claret Asset Management’s Novartis NVS Stock Holding History

Claret Asset Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Hold	0	–	–	–	226
2023 Q4	–	Sell	-2,411	Closed	-$246K	–	194
2023 Q3	$246K	Hold	2,411	–	–	0.05%	120
2023 Q2	$243K	Buy	+2,411	New	+$241K	0.05%	124

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Claret Asset Management's NVS Position: Q1 2025 in Review

Claret Asset Management held its Novartis (NVS) position steady in Q1 2025 at 0 shares worth $229K. The position accounts for 0.03% of the portfolio, ranked #226.

Claret Asset Management first reported a position in NVS in Q2 2023 and has held it in 2 quarters since. The position peaked at $246K in Q3 2023. 1,356 funds tracked by Wall St. Rank hold NVS as of Q1 2025.

Claret Asset Management held 0 shares of Novartis worth $229K as of Q1 2025.
Claret Asset Management left its Novartis share count unchanged in Q1 2025.
Novartis made up 0.03% of Claret Asset Management's portfolio in Q1 2025, its #226 holding.
Claret Asset Management first reported a position in Novartis in Q2 2023 and has held it in 2 quarters since.
Claret Asset Management's Novartis position peaked at $246K in Q3 2023.
1,356 funds tracked by Wall St. Rank held Novartis as of Q1 2025.

Based on Claret Asset Management's 13F filing for Q1 2025, filed 13 May 2025.